Mechanisms of vascular damage in systemic sclerosis.
Although being classified as autoimmune connective tissue disease, dominant components of the pathophysiology of systemic sclerosis (SSc) consists of mechanisms of vascular damage, which can occur early in the course of the disease. Amongst them are abnormal vasoreactivity, hypoxia, insufficient neoangiogenesis and direct damage of vascular and perivascular cells. They result in a decreased capillary blood flow, and subsequently in clinically overt symptoms such as Raynaud's syndrome and fingertip ulcers. In addition, in active disease vascular pathology can affect various other organs, predominantly the lung, the kidney, the heart but also the gastrointestinal tract. Vascular pathology contributes also significantly to overall morbidity and mortality in SSc patients and reduces life expectancy by at least a decade. Fortunately, molecular biology has revealed a number of underlying pathways on the cellular and subcellular levels, including key factors of the aberrant function of (peri)vascular cells and autoimmune effector cells, the dysregulation of vasoconstrictive molecules and their receptors, the upregulation of intracellular signaling kinases and the altered balance of hypoxia-induced vascular growth factors. This increasing knowledge of vascular pathology in SSc has also resulted in novel therapeutic approaches ranging from endothelin antagonists to application of progenitor cells to counteract this aberrant vascular pathology and to support the repair of the dysfunctional vasculature.
Department of Internal Medicine and Rheumatology, Kerckhoff Clinic, Justus-Liebig University Giessen, Benekestrasse 2-8, D-61231, Bad Nauheim, Germany. u.mueller-ladner@kerckhoff-klinik.de
Ulf
U
Müller-Ladner
Oliver
O
Distler
Lidia
L
Ibba-Manneschi
Elena
E
Neumann
Steffen
S
Gay
D017209:Apoptosis / Q000502:physiology; D001323:Autoantibodies / Q000097:blood; D001808:Blood Vessels / Q000378:metabolism*; D019332:Endothelin-1 / Q000378:metabolism; D004730:Endothelium, Vascular / Q000378:metabolism*; D044127:Epigenesis, Genetic / Q000502:physiology; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000276:immunology*; D020641:Polymorphism, Single Nucleotide; D012595:Scleroderma, Systemic / Q000150:complications* / Q000276:immunology*; D014652:Vascular Diseases / Q000235:genetics / Q000276:immunology*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D001323:Autoantibodies; D019332:Endothelin-1; C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D042461:Vascular Endothelial Growth Factor A; D018799:Intercellular Adhesion Molecule-1